Philippe Moreau
0000-0003-1780-8746
Publication & Citation Trends
Publications
0 total
Bimodal PET/CT and PET/MRI imaging in multiple myeloma/prostate cancer restaging and response to BCMA-targeted CAR T-therapy assessment
Cited by 0
Semantic Scholar
Teclistamab for Relapsed or Refractory Multiple Myeloma: A Review of Efficacy, Safety, Resistance Mechanisms and Future Directions
Cited by 1
Semantic Scholar
CAR+ T-Cell Lymphoma after Cilta-cel Therapy for Relapsed or Refractory Myeloma.
Cited by 29
Semantic Scholar
Unusual Sole Extramedullary Diffuse Kidney Involvement in Multiple Myeloma Initial Workup Using 2-[18F]FDG-PET/CT Imaging.
Cited by 0
Semantic Scholar
Combined inhibition of CTPS1 and ATR is a metabolic vulnerability in p53‐deficient myeloma cells OA
Cited by 0
Semantic Scholar
Mechanisms of resistance to bispecific T-cell engagers in multiple myeloma and their clinical implications OA
Cited by 29
Semantic Scholar
Abstract 1238: ISB 2001, a BCMA and CD38 dual targeting T cell engager, demonstrates superior cytotoxicity relative to teclistamab in the samples of patient relapsing from CD38 and BCMA targeted immunotherapies
Cited by 0
Semantic Scholar
Research Topics
Multiple Myeloma Research and Treatments
(1446)
Protein Degradation and Inhibitors
(592)
Peptidase Inhibition and Analysis
(356)
Cancer Treatment and Pharmacology
(279)
Chronic Lymphocytic Leukemia Research
(198)
Affiliations
Université Paris-Sud
Rutgers, The State University of New Jersey
Université de Tours
Délégation Paris 5
Northwestern University